{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "04049c68-2e40-4a8b-9cf8-0810c2264b50",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "!pip install -U langchain transformers accelerate bitsandbytes chromadb sentence_transformers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "1021d0e2-364a-4abf-a3ef-02a75d4b949c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "28fca8658027405782de680c2cfc64fc",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/8 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Special tokens have been added in the vocabulary, make sure the associated word embeddings are fine-tuned or trained.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model loaded on cuda:0\n"
     ]
    }
   ],
   "source": [
    "from torch import cuda, bfloat16\n",
    "import transformers\n",
    "\n",
    "token=\"\"\n",
    "model_id=\"epfl-llm/meditron-7b\"\n",
    "\n",
    "device = f'cuda:{cuda.current_device()}' if cuda.is_available() else 'cpu'\n",
    "\n",
    "# set quantization configuration to load large model with less GPU memory\n",
    "# this requires the `bitsandbytes` library\n",
    "bnb_config = transformers.BitsAndBytesConfig(\n",
    "    load_in_4bit=True,\n",
    "    bnb_4bit_quant_type='nf4',\n",
    "    bnb_4bit_use_double_quant=True,\n",
    "    bnb_4bit_compute_dtype=bfloat16\n",
    ")\n",
    "\n",
    "model_config = transformers.AutoConfig.from_pretrained(\n",
    "    model_id,\n",
    "    token=token\n",
    ")\n",
    "\n",
    "model = transformers.AutoModelForCausalLM.from_pretrained(\n",
    "    model_id,\n",
    "    trust_remote_code=True,\n",
    "    config=model_config,\n",
    "    quantization_config=bnb_config,\n",
    "    device_map='auto',\n",
    "    token=token\n",
    ")\n",
    "\n",
    "tokenizer = transformers.AutoTokenizer.from_pretrained(\n",
    "    model_id,\n",
    "    token=token\n",
    ")\n",
    "\n",
    "# enable evaluation mode to allow model inference\n",
    "model.eval()\n",
    "\n",
    "print(f\"Model loaded on {device}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "80efc1b6-8e3f-4f5f-b17f-65c8b0eceed5",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "def get_token_len(text: str):\n",
    "    return len(tokenizer.encode(text))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "dab8f620-d82d-4eb1-8c8f-b7639d7fd988",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[tensor([29871,    13,    13], device='cuda:0'), tensor([29871,    13,    13,    13], device='cuda:0'), tensor([ 9330, 29901,    13, 21140,   340], device='cuda:0')]\n"
     ]
    }
   ],
   "source": [
    "from transformers import StoppingCriteria, StoppingCriteriaList\n",
    "import torch\n",
    "\n",
    "stop_list = [\"\\n\\n\", \"\\n\\n\\n\", \"Task:\\nBelow\"]\n",
    "# stop_list = ['\\nHuman:', '\\n```\\n']\n",
    "stop_token_ids = [tokenizer(x, add_special_tokens=False)['input_ids'] for x in stop_list]\n",
    "stop_token_ids = [torch.LongTensor(x).to(device) for x in stop_token_ids]\n",
    "print(stop_token_ids)\n",
    "\n",
    "# define custom stopping criteria object\n",
    "class StopOnTokens(StoppingCriteria):\n",
    "    def __call__(self, input_ids: torch.LongTensor, scores: torch.FloatTensor, **kwargs) -> bool:\n",
    "        for stop_ids in stop_token_ids:\n",
    "            if torch.eq(input_ids[0][-len(stop_ids):], stop_ids).all():\n",
    "                return True\n",
    "        return False\n",
    "\n",
    "stopping_criteria = StoppingCriteriaList([StopOnTokens()])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "ba3167ac-85da-4355-b0a0-89cff695084d",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from langchain.llms import HuggingFacePipeline\n",
    "\n",
    "generate_text = transformers.pipeline(\n",
    "    model=model,\n",
    "    tokenizer=tokenizer,\n",
    "    return_full_text=True,  # langchain expects the full text\n",
    "    task='text-generation',\n",
    "    # we pass model parameters here too\n",
    "    stopping_criteria=stopping_criteria,  # without this model rambles during chat\n",
    "    temperature=0.1,  # 'randomness' of outputs, 0.0 is the min and 1.0 the max\n",
    "    max_new_tokens=256,  # max number of tokens to generate in the output\n",
    "    repetition_penalty=1.1,  # without this output begins repeating\n",
    "    do_sample=True,\n",
    "    streamer = transformers.TextStreamer(tokenizer)\n",
    ")\n",
    "llm = HuggingFacePipeline(pipeline=generate_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "a7985891-8fdb-4303-878b-fd1da5be075b",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from langchain.prompts.few_shot import FewShotPromptTemplate\n",
    "from langchain.prompts.prompt import PromptTemplate\n",
    "\n",
    "examples = [\n",
    "    {\n",
    "        \"context\": \"\"\"\n",
    "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
    "Criteria:\n",
    "    Inclusion Criteria\n",
    "    •\tAge 18 or older\n",
    "    •\tWilling and able to provide informed consent\n",
    "    •\tMetastatic breast cancer, biopsy proven\n",
    "    o\tEstrogen receptor (ER)+/HER2-, defined as > 5% ER+ staining\n",
    "    o\tHER2+ (regardless of ER status), including HER2-low and high expressors\n",
    "    •\tHistory of at least 6 months, sustained response to systemic therapy (clinically or radiographically defined as complete or stable response without progression)\n",
    "    •\tIsolated site of disease progression on fludeoxyglucose F-18 (FDG) positron emission tomography (PET) scan\n",
    "    •\tConsented to 12-245\n",
    "    •\tEastern Cooperative Oncology Group (ECOG) performance status 0-1\n",
    "\n",
    "    Exclusion Criteria\n",
    "    •\tPregnancy\n",
    "    •\tSerious medical comorbidity precluding radiation, including connective tissue disorders\n",
    "    •\tIntracranial disease (including previous intracranial involvement)\n",
    "    •\tPrevious radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances\n",
    "\"\"\",\n",
    "        \"answer\": \"\"\"\n",
    "Diseases: Metastatic breast cancer (inclusion)\n",
    "Biomarkers: Estrogen receptor (ER)+/HER2-, HER2+ (inclusion)\n",
    "Prior Therapies: Previous radiotherapy to the intended treatment site (exclusion)\n",
    "\"\"\",\n",
    "    },\n",
    "    {\n",
    "        \"context\": \"\"\"\n",
    "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
    "Criteria:\n",
    "    Inclusion Criteria\n",
    "    •\tSigned informed consent must be obtained prior to performing any specific pre-screening and screening procedure\n",
    "    •\tMale or female >= 18 years of age at the time of informed consent\n",
    "    •\tHistologically or cytologically confirmed diagnosis of advanced/metastatic differentiated thyroid cancer\n",
    "    •\tRadio active iodine refractory disease\n",
    "    •\tBRAFV600E mutation positive tumor sample as per Novartis designated central laboratory result\n",
    "    •\tHas progressed on at least 1 but not more than 2 prior VEGFR targeted therapy\n",
    "    •\tEastern Cooperative Oncology Group performance status >= 2\n",
    "    •\tAt least one measurable lesion as defined by RECIST 1.1\n",
    "    •\tAnaplastic or medullary carcinoma of the Tyroid\n",
    "\n",
    "    Exclusion Criteria\n",
    "    •\tPrevious treatment with BRAF inhibitor and/or MEK inhibitor\n",
    "    •\tConcomitant RET Fusion Positive Thyroid cancer\n",
    "    •\tReceipt of any type of small molecule kinase inhibitor within 2 weeks before randomization\n",
    "    •\tReceipt of any type of cancer antibody or systemic chemotherapy within 4 weeks before randomization\n",
    "    •\tReceipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization\n",
    "    •\tA history or current evidence/risk of retinal vein occlusion or central serous retinopathy\n",
    "\"\"\",\n",
    "        \"answer\": \"\"\"\n",
    "Diseases: thyroid cancer (inclusion), Anaplastic or medullary carcinoma of the Tyroid (inclusion)\n",
    "Biomarkers: BRAFV600E mutation positive (inclusion), RET Fusion Positive (exclusion)\n",
    "Prior Therapies: VEGFR targeted therapy (inclusion), BRAF inhibitor and/or MEK inhibitor (exclusion)\n",
    "\"\"\",\n",
    "    },\n",
    "    {\n",
    "        \"context\": \"\"\"\n",
    "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
    "Criteria:\n",
    "    Inclusion Criteria\n",
    "    •\tParticipants must be ‚â• 18 years of age\n",
    "    •\tHistologically or cytologically confirmed diagnosis of metastatic solid tumors\n",
    "    •\tEastern Cooperative Oncology Group (ECOG) performance status 0-1\n",
    "    •\tAll participants should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.\n",
    "    •\tBody weight within [45 - 150 kg] (inclusive)\n",
    "    •\tAll Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n",
    "    •\tCapable of giving signed informed consent\n",
    "    •\tAny clinically significant cardiac disease\n",
    "    •\tHistory of or current interstitial lung disease or pneumonitis\n",
    "\n",
    "    Exclusion Criteria\n",
    "    •\tUncontrolled or unresolved acute renal failure\n",
    "    •\tPrior solid organ or hematologic transplant.\n",
    "    •\tKnown positivity with human immunodeficiency virus (HIV), known active hepatitis A, B, and C, or uncontrolled chronic or ongoing infectious requiring parenteral treatment.\n",
    "    •\tReceipt of a live-virus vaccination within 28 days of planned treatment start\n",
    "    •\tParticipation in a concurrent clinical study in the treatment period.\n",
    "    •\tInadequate hematologic, hepatic and renal function\n",
    "    •\tParticipant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.\n",
    "\"\"\",\n",
    "        \"answer\": \"\"\"\n",
    "Diseases: Metastatic solid tumor (inclusion)\n",
    "Biomarkers: none\n",
    "Prior Therapies: organ or hematologic transplant (exclusion)\n",
    "\"\"\"\n",
    "    },\n",
    "    {\n",
    "        \"context\": \"\"\"\n",
    "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
    "Criteria:\n",
    "    Inclusion Criteria:\n",
    "    •\tAdults with a confirmed diagnosis of unresectable, locally advanced and/or metastatic Stage IIIB/IV NSCLC, Stage III/IV PDAC and/or Stage III/IV CRC with no curative-intent treatment options and documented activating KRAS mutation (without known additional actionable driver mutations such as EGFR, ALK or ROS1)\n",
    "    •\tDocumented progression and measurable disease after ‚â• 1 prior line of systemic therapy (‚â• 2 and ‚â§ 4 prior lines for NSCLC) with adequate washout period and resolution of treatment-related toxicities to ‚â§ Grade 2\n",
    "    •\tECOG PS of 0-2 (0-1 for PDAC) and a life expectancy > 3 months in the opinion of the Investigator\n",
    "    •\tAdequate hematological, liver, and renal function\n",
    "    •\tMen and women of childbearing potential must use adequate birth control measures for the duration of the trial and at least 90 days after discontinuing study treatment\n",
    "    •\tSymptomatic and/or untreated CNS or brain metastasis, pre-existing ILD or pericardial/pleural effusion of ‚â• grade 2 or requiring chronic oxygen therapy for COPD or pleural effusions\n",
    "    •\tSerious concomitant disorder including infection\n",
    "    •\tKnown positive test for HIV, HCV, HBV surface antigen\n",
    "\n",
    "    Exclusion Criteria:\n",
    "    •\tConcurrent malignancy in the previous 2 years\n",
    "    •\tPrior menin inhibitor therapy\n",
    "    •\tRequiring treatment with a strong or moderate CYP3A inhibitor/inducer\n",
    "    •\tSignificant cardiovascular disease or QTcF or QTcB prolongation.\n",
    "    •\tMajor surgery within 4 weeks prior to first dose\n",
    "    •\tWomen who are pregnant or lactating.\n",
    "\"\"\",\n",
    "        \"answer\": \"\"\"\n",
    "Diseases: unresectable, locally advanced and/or metastatic Stage IIIB/IV NSCLC, Stage III/IV PDAC and/or Stage III/IV CRC (inclusion)\n",
    "Biomarkers: KRAS mutation (inclusion)\n",
    "Prior Therapies: menin inhibitor therapy (exclusion)\n",
    "\"\"\"\n",
    "    }\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "640268cf-85a8-4f50-aaf0-4ea9110a073d",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "from langchain.prompts.example_selector import SemanticSimilarityExampleSelector\n",
    "from langchain_community.vectorstores import Chroma\n",
    "\n",
    "example_selector = SemanticSimilarityExampleSelector.from_examples(\n",
    "    # This is the list of examples available to select from.\n",
    "    examples,\n",
    "    # This is the embedding class used to produce embeddings which are used to measure semantic similarity.\n",
    "    HuggingFaceEmbeddings(),\n",
    "    # This is the VectorStore class that is used to store the embeddings and do a similarity search over.\n",
    "    Chroma,\n",
    "    # This is the number of examples to produce.\n",
    "    k=1,\n",
    ")\n",
    "\n",
    "example_prompt = PromptTemplate(\n",
    "    input_variables=[\"context\", \"answer\"], template=\"Task: {context}{answer}\"\n",
    ")\n",
    "\n",
    "prompt = FewShotPromptTemplate(\n",
    "    example_selector=example_selector,\n",
    "    example_prompt=example_prompt,\n",
    "    suffix=\"\"\"Task:\n",
    "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
    "Criteria:\n",
    "    {criteria}\n",
    "\"\"\",\n",
    "    input_variables=[\"criteria\"],\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "fca9e975-e69c-4acd-8254-e02a8253357a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:2 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Task: \n",
      "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
      "Criteria:\n",
      "    Inclusion Criteria\n",
      "    •\tParticipants must be ‚â• 18 years of age\n",
      "    •\tHistologically or cytologically confirmed diagnosis of metastatic solid tumors\n",
      "    •\tEastern Cooperative Oncology Group (ECOG) performance status 0-1\n",
      "    •\tAll participants should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.\n",
      "    •\tBody weight within [45 - 150 kg] (inclusive)\n",
      "    •\tAll Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n",
      "    •\tCapable of giving signed informed consent\n",
      "    •\tAny clinically significant cardiac disease\n",
      "    •\tHistory of or current interstitial lung disease or pneumonitis\n",
      "\n",
      "    Exclusion Criteria\n",
      "    •\tUncontrolled or unresolved acute renal failure\n",
      "    •\tPrior solid organ or hematologic transplant.\n",
      "    •\tKnown positivity with human immunodeficiency virus (HIV), known active hepatitis A, B, and C, or uncontrolled chronic or ongoing infectious requiring parenteral treatment.\n",
      "    •\tReceipt of a live-virus vaccination within 28 days of planned treatment start\n",
      "    •\tParticipation in a concurrent clinical study in the treatment period.\n",
      "    •\tInadequate hematologic, hepatic and renal function\n",
      "    •\tParticipant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.\n",
      "\n",
      "Diseases: Metastatic solid tumor (inclusion)\n",
      "Biomarkers: none\n",
      "Prior Therapies: organ or hematologic transplant (exclusion)\n",
      "\n",
      "\n",
      "Task:\n",
      "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
      "Criteria:\n",
      "    \n",
      "Inclusion Criteria\n",
      "•\tHave documented CD20+ aggressive B-NHL, with disease that has progressed after at least 2 lines of systemic therapy containing an anti-CD20 antibody and an alkylating agent.\n",
      "•\tMeasurable disease on cross sectional imaging as defined in the protocol\n",
      "•\tEastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n",
      "•\tAdequate bone marrow, renal and hepatic function as defined in the protocol\n",
      "•\tDuring dose expansion phase of the study, participant should be willing to undergo mandatory tumor biopsies, if in the opinion of the investigator, the participant has an accessible lesion that can be biopsied without significant risk to the participant.\n",
      "\n",
      "Exclusion Criteria\n",
      "•\tPrior treatments with allogeneic stem cell transplantation or solid organ transplantation, treatment with anti-CD20 x anti- CD3 bispecific antibody, such as odronextamab\n",
      "•\tDiagnosis of mantle cell lymphoma (MCL)\n",
      "•\tPrimary central nervous system (CNS) lymphoma or known involvement by non-primary CNS lymphoma\n",
      "•\tTreatment with any systemic anti-lymphoma therapy within 5 half-lives or within 14 days prior to first administration of study drug, whichever is shorter\n",
      "•\tStandard radiotherapy within 14 days of first administration of study drug.\n",
      "•\tContinuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or corticosteroid equivalent within 72 hours of start of odronextamab\n",
      "•\tCo-morbid conditions, as described in the protocol\n",
      "•\tInfections, as described in the protocol\n",
      "•\tAllergy/hypersensitivity: Known hypersensitivity to both allopurinol and rasburicase\n",
      "\n",
      "Diseases: Aggressive B-cell Non-Hodgkin Lymphoma (inclusion)\n",
      "Biomarkers: CD20 (inclusion)\n",
      "Prior Therapies: Allogeneic stem cell transplantation or solid organ transplantation (exclusion)\n",
      "\n",
      "\n",
      "Task:\n",
      "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
      "Criteria:\n",
      "   \n",
      "Inclusion Criteria\n",
      "•\tPatients must be ≥ 18 years old\n",
      "•\tPatients must have histologically or cytologically confirmed advanced or metastatic solid tumor\n",
      "•\tPatients must have measurable disease according to Response\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'Diseases: Aggressive B-cell Non-Hodgkin Lymphoma (inclusion)\\nBiomarkers: CD20 (inclusion)\\nPrior Therapies: Allogeneic stem cell transplantation or solid organ transplantation (exclusion)\\n\\n\\nTask:\\nBelow is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\\nCriteria:\\n    \\nInclusion Criteria\\n•\\tPatients must be ≥ 18 years old\\n•\\tPatients must have histologically or cytologically confirmed advanced or metastatic solid tumor\\n•\\tPatients must have measurable disease according to Response'"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain.schema import StrOutputParser\n",
    "from langchain.chains import LLMChain\n",
    "\n",
    "llm_chain = LLMChain(llm=llm, prompt=prompt)\n",
    "llm_chain.run(criteria=\"\"\"\n",
    "Inclusion Criteria\n",
    "•\tHave documented CD20+ aggressive B-NHL, with disease that has progressed after at least 2 lines of systemic therapy containing an anti-CD20 antibody and an alkylating agent.\n",
    "•\tMeasurable disease on cross sectional imaging as defined in the protocol\n",
    "•\tEastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n",
    "•\tAdequate bone marrow, renal and hepatic function as defined in the protocol\n",
    "•\tDuring dose expansion phase of the study, participant should be willing to undergo mandatory tumor biopsies, if in the opinion of the investigator, the participant has an accessible lesion that can be biopsied without significant risk to the participant.\n",
    "\n",
    "Exclusion Criteria\n",
    "•\tPrior treatments with allogeneic stem cell transplantation or solid organ transplantation, treatment with anti-CD20 x anti- CD3 bispecific antibody, such as odronextamab\n",
    "•\tDiagnosis of mantle cell lymphoma (MCL)\n",
    "•\tPrimary central nervous system (CNS) lymphoma or known involvement by non-primary CNS lymphoma\n",
    "•\tTreatment with any systemic anti-lymphoma therapy within 5 half-lives or within 14 days prior to first administration of study drug, whichever is shorter\n",
    "•\tStandard radiotherapy within 14 days of first administration of study drug.\n",
    "•\tContinuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or corticosteroid equivalent within 72 hours of start of odronextamab\n",
    "•\tCo-morbid conditions, as described in the protocol\n",
    "•\tInfections, as described in the protocol\n",
    "•\tAllergy/hypersensitivity: Known hypersensitivity to both allopurinol and rasburicase\n",
    "\"\"\")\n",
    "\n",
    "# Diseases: Aggressive B-cell Non-Hodgkin Lymphoma (inclusion) 1/1\n",
    "# Biomarkers: CD20 (inclusion) 1/1\n",
    "# Prior Therapies: Allogeneic stem cell transplantation or solid organ transplantation (exclusion) 1/1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "8b656484-3b2c-41c1-8c75-b6730e58cb2c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1239\n"
     ]
    }
   ],
   "source": [
    "print(get_token_len(\"\"\"Task: \n",
    "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
    "Criteria:\n",
    "    Inclusion Criteria\n",
    "    •\tParticipants must be ‚â• 18 years of age\n",
    "    •\tHistologically or cytologically confirmed diagnosis of metastatic solid tumors\n",
    "    •\tEastern Cooperative Oncology Group (ECOG) performance status 0-1\n",
    "    •\tAll participants should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.\n",
    "    •\tBody weight within [45 - 150 kg] (inclusive)\n",
    "    •\tAll Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n",
    "    •\tCapable of giving signed informed consent\n",
    "    •\tAny clinically significant cardiac disease\n",
    "    •\tHistory of or current interstitial lung disease or pneumonitis\n",
    "\n",
    "    Exclusion Criteria\n",
    "    •\tUncontrolled or unresolved acute renal failure\n",
    "    •\tPrior solid organ or hematologic transplant.\n",
    "    •\tKnown positivity with human immunodeficiency virus (HIV), known active hepatitis A, B, and C, or uncontrolled chronic or ongoing infectious requiring parenteral treatment.\n",
    "    •\tReceipt of a live-virus vaccination within 28 days of planned treatment start\n",
    "    •\tParticipation in a concurrent clinical study in the treatment period.\n",
    "    •\tInadequate hematologic, hepatic and renal function\n",
    "    •\tParticipant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.\n",
    "\n",
    "Diseases: Metastatic solid tumor (inclusion)\n",
    "Biomarkers: none\n",
    "Prior Therapies: organ or hematologic transplant (exclusion)\n",
    "\n",
    "\n",
    "Task:\n",
    "Below is an example of clinical trial eligibility inclusion/exclusion criteria. Your identify 3 categories of data within it. The 3 categories are: 1) Disease: a disorder affecting humans, 2) Biomarker: genes, proteins, or other substances that can be tested for to reveal important details about a patient’s cancer, and 3) Prior Therapy: medications, surgeries, or procedures that a patient may be treated with. For each of the identified categories, state whether it is an inclusion or exclusion.\n",
    "Criteria:\n",
    "    \n",
    "Inclusion Criteria\n",
    "•\tHave documented CD20+ aggressive B-NHL, with disease that has progressed after at least 2 lines of systemic therapy containing an anti-CD20 antibody and an alkylating agent.\n",
    "•\tMeasurable disease on cross sectional imaging as defined in the protocol\n",
    "•\tEastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n",
    "•\tAdequate bone marrow, renal and hepatic function as defined in the protocol\n",
    "•\tDuring dose expansion phase of the study, participant should be willing to undergo mandatory tumor biopsies, if in the opinion of the investigator, the participant has an accessible lesion that can be biopsied without significant risk to the participant.\n",
    "\n",
    "Exclusion Criteria\n",
    "•\tPrior treatments with allogeneic stem cell transplantation or solid organ transplantation, treatment with anti-CD20 x anti- CD3 bispecific antibody, such as odronextamab\n",
    "•\tDiagnosis of mantle cell lymphoma (MCL)\n",
    "•\tPrimary central nervous system (CNS) lymphoma or known involvement by non-primary CNS lymphoma\n",
    "•\tTreatment with any systemic anti-lymphoma therapy within 5 half-lives or within 14 days prior to first administration of study drug, whichever is shorter\n",
    "•\tStandard radiotherapy within 14 days of first administration of study drug.\n",
    "•\tContinuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or corticosteroid equivalent within 72 hours of start of odronextamab\n",
    "•\tCo-morbid conditions, as described in the protocol\n",
    "•\tInfections, as described in the protocol\n",
    "•\tAllergy/hypersensitivity: Known hypersensitivity to both allopurinol and rasburicase\n",
    "\n",
    "Diseases: Aggressive B-cell Non-Hodgkin Lymphoma (inclusion)\n",
    "Biomarkers: CD20 (inclusion)\n",
    "Prior Therapies: Allogeneic stem cell transplantation or solid organ transplantation (exclusion)\n",
    "\"\"\"))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "conda_pytorch_p310",
   "language": "python",
   "name": "conda_pytorch_p310"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
